Nkarta, Inc. Operating Expenses
Nkarta, Inc. (NKTX) reported Operating Expenses of $43.13 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-10
- Nkarta, Inc. operating expenses for the quarter ending 2026-06-30 was $43.13M, a 58.64% increase year-over-year.
- Nkarta, Inc. operating expenses for the quarter ending 2026-03-31 was $30.88M, a 15.56% decline year-over-year.
- Nkarta, Inc. operating expenses for the quarter ending 2025-12-31 was $30.96M, a 0.12% increase year-over-year.
- Nkarta, Inc. operating expenses for the quarter ending 2025-09-30 was $27.29M, a 19.26% decline year-over-year.
- Nkarta, Inc. operating expenses for fiscal 2025 was $122.00M, a 4.83% decline from fiscal 2024.
- Nkarta, Inc. operating expenses for fiscal 2024 was $128.19M, a 2.63% decline from fiscal 2023.
- Nkarta, Inc. operating expenses for fiscal 2023 was $131.65M, a 10.67% increase from fiscal 2022.
- Nkarta, Inc. operating expenses for fiscal 2022 was $118.95M, a 37.63% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $43.13M 10-Q · filed 2026-08-10 | $74.00M 10-Q · filed 2026-08-10 | $104.97M derived: sum of 3 quarters · filed 2026-08-10 | $132.25M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2026-03-31 | $30.88M 10-Q · filed 2026-05-12 | $61.84M derived: sum of 2 quarters · filed 2026-05-12 | $89.12M derived: sum of 3 quarters · filed 2026-05-12 | $116.31M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-12-31 | $30.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $58.25M derived: sum of 2 quarters · filed 2026-03-25 | $85.43M derived: sum of 3 quarters · filed 2026-08-10 | $122.00M 10-K · filed 2026-03-25 | ||
| 2025-09-30 | $27.29M 10-Q · filed 2025-11-10 | $54.47M derived: sum of 2 quarters · filed 2026-08-10 | $91.04M 10-Q · filed 2025-11-10 | $121.96M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-06-30 | $27.19M 10-Q · filed 2026-08-10 | $63.75M 10-Q · filed 2026-08-10 | $94.67M derived: sum of 3 quarters · filed 2026-08-10 | $128.47M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-03-31 | $36.56M 10-Q · filed 2026-05-12 | $67.49M derived: sum of 2 quarters · filed 2026-05-12 | $101.28M derived: sum of 3 quarters · filed 2026-05-12 | $132.00M derived: sum of 4 quarters · filed 2026-05-12 | ||
| 2024-12-31 | $30.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $64.72M derived: sum of 2 quarters · filed 2026-03-25 | $95.43M derived: sum of 3 quarters · filed 2026-03-25 | $128.19M 10-K · filed 2026-03-25 | ||
| 2024-09-30 | $33.79M 10-Q · filed 2025-11-10 | $64.51M derived: sum of 2 quarters · filed 2025-11-10 | $97.27M 10-Q · filed 2025-11-10 | $128.46M derived: sum of 4 quarters · filed 2025-11-10 | ||
| 2024-06-30 | $30.71M 10-Q · filed 2025-08-12 | $63.48M 10-Q · filed 2025-08-12 | $94.66M derived: sum of 3 quarters · filed 2025-08-12 | $123.96M derived: sum of 4 quarters · filed 2025-08-12 | ||
| 2024-03-31 | $32.76M 10-Q · filed 2025-05-14 | $63.95M derived: sum of 2 quarters · filed 2025-05-14 | $93.24M derived: sum of 3 quarters · filed 2025-05-14 | $130.10M derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2023-12-31 | $31.18M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $60.48M derived: sum of 2 quarters · filed 2025-03-26 | $97.34M derived: sum of 3 quarters · filed 2025-03-26 | $131.65M 10-K · filed 2025-03-26 | ||
| 2023-09-30 | $29.29M 10-Q · filed 2024-11-07 | $66.15M derived: sum of 2 quarters · filed 2024-11-07 | $100.47M 10-Q · filed 2024-11-07 | $135.45M derived: sum of 4 quarters · filed 2024-11-07 | ||
| 2023-06-30 | $36.86M 10-Q · filed 2024-08-13 | $71.17M 10-Q · filed 2024-08-13 | $106.15M derived: sum of 3 quarters · filed 2024-08-13 | $136.42M derived: sum of 4 quarters · filed 2024-08-13 | ||
| 2023-03-31 | $34.31M 10-Q · filed 2024-05-09 | $69.30M derived: sum of 2 quarters · filed 2024-05-09 | $99.56M derived: sum of 3 quarters · filed 2024-05-09 | $127.17M derived: sum of 4 quarters · filed 2024-05-09 | ||
| 2022-12-31 | $34.98M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $65.25M derived: sum of 2 quarters · filed 2024-03-21 | $92.86M derived: sum of 3 quarters · filed 2024-03-21 | $118.95M 10-K · filed 2024-03-21 | ||
| 2022-09-30 | $30.26M 10-Q · filed 2023-11-09 | $57.87M derived: sum of 2 quarters · filed 2023-11-09 | $83.97M 10-Q · filed 2023-11-09 | $106.86M derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | $27.61M 10-Q · filed 2023-08-10 | $53.71M 10-Q · filed 2023-08-10 | $76.60M derived: sum of 3 quarters · filed 2023-08-10 | $99.03M derived: sum of 4 quarters · filed 2023-08-10 | ||
| 2022-03-31 | $26.10M 10-Q · filed 2023-05-11 | $48.98M derived: sum of 2 quarters · filed 2023-05-11 | $71.41M derived: sum of 3 quarters · filed 2023-05-11 | $93.05M derived: sum of 4 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $22.89M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $45.31M derived: sum of 2 quarters · filed 2023-03-16 | $66.95M derived: sum of 3 quarters · filed 2023-03-16 | $86.43M 10-K · filed 2023-03-16 | ||
| 2021-09-30 | $22.43M 10-Q · filed 2022-11-09 | $44.06M derived: sum of 2 quarters · filed 2022-11-09 | $63.54M 10-Q · filed 2022-11-09 | $81.54M derived: sum of 4 quarters · filed 2022-11-09 | ||
| 2021-06-30 | $21.63M 10-Q · filed 2022-08-11 | $41.11M 10-Q · filed 2022-08-11 | $59.11M derived: sum of 3 quarters · filed 2022-08-11 | $72.86M derived: sum of 4 quarters · filed 2022-08-11 | ||
| 2021-03-31 | $19.48M 10-Q · filed 2022-05-12 | $37.48M derived: sum of 2 quarters · filed 2022-05-12 | $51.23M derived: sum of 3 quarters · filed 2022-05-12 | $61.58M derived: sum of 4 quarters · filed 2022-05-12 | ||
| 2020-12-31 | $18.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $31.74M derived: sum of 2 quarters · filed 2022-03-17 | $42.10M derived: sum of 3 quarters · filed 2022-03-17 | $51.51M 10-K · filed 2022-03-17 | ||
| 2020-09-30 | $13.75M 10-Q · filed 2021-11-10 | $24.10M derived: sum of 2 quarters · filed 2021-11-10 | $33.51M 10-Q · filed 2021-11-10 | $42.16M derived: sum of 4 quarters · filed 2021-11-10 | ||
| 2020-06-30 | $10.36M 10-Q · filed 2021-08-12 | $10.36M 10-Q · filed 2020-08-20 | $19.76M 10-Q · filed 2021-08-12 | $19.76M 10-Q · filed 2020-08-20 | $28.41M derived: sum of 3 quarters · filed 2021-08-12 | $34.32M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $9.41M 10-Q · filed 2021-05-13 | $18.06M derived: sum of 2 quarters · filed 2021-05-13 | $23.96M derived: sum of 3 quarters · filed 2021-05-13 | $28.64M derived: sum of 4 quarters · filed 2021-05-13 | ||
| 2019-12-31 | $8.65M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $14.56M derived: sum of 2 quarters · filed 2021-03-25 | $19.23M derived: sum of 3 quarters · filed 2021-03-25 | $22.46M 10-K · filed 2021-03-25 | ||
| 2019-09-30 | $5.91M 10-Q · filed 2020-11-12 | $10.58M derived: sum of 2 quarters · filed 2020-11-12 | $13.82M 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | $4.67M 10-Q · filed 2020-08-20 | $7.91M 10-Q · filed 2020-08-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |